auph-20241231

false2024FY00016006200.3333iso4217:USDxbrli:sharesiso4217:USDxbrli:sharesauph:customerxbrli:pureauph:segmentiso4217:CHFutr:sqftauph:extension_optionauph:purchasePeriodauph:patent00016006202024-01-012024-12-3100016006202024-06-3000016006202025-02-2500016006202024-10-012024-12-3100016006202024-12-3100016006202023-12-310001600620us-gaap:RelatedPartyMember2024-12-310001600620us-gaap:RelatedPartyMember2023-12-310001600620us-gaap:ProductMember2024-01-012024-12-310001600620us-gaap:ProductMember2023-01-012023-12-310001600620us-gaap:ProductMember2022-01-012022-12-310001600620auph:LicenseCollaborationAndRoyaltyRevenueMember2024-01-012024-12-310001600620auph:LicenseCollaborationAndRoyaltyRevenueMember2023-01-012023-12-310001600620auph:LicenseCollaborationAndRoyaltyRevenueMember2022-01-012022-12-3100016006202023-01-012023-12-3100016006202022-01-012022-12-310001600620us-gaap:CommonStockMember2021-12-310001600620us-gaap:AdditionalPaidInCapitalMember2021-12-310001600620us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001600620us-gaap:RetainedEarningsMember2021-12-3100016006202021-12-310001600620us-gaap:CommonStockMember2022-01-012022-12-310001600620us-gaap:AdditionalPaidInCapitalMember2022-01-012022-12-310001600620us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-12-310001600620us-gaap:RetainedEarningsMember2022-01-012022-12-310001600620us-gaap:CommonStockMember2022-12-310001600620us-gaap:AdditionalPaidInCapitalMember2022-12-310001600620us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001600620us-gaap:RetainedEarningsMember2022-12-3100016006202022-12-310001600620us-gaap:CommonStockMember2023-01-012023-12-310001600620us-gaap:AdditionalPaidInCapitalMember2023-01-012023-12-310001600620us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-12-310001600620us-gaap:RetainedEarningsMember2023-01-012023-12-310001600620us-gaap:CommonStockMember2023-12-310001600620us-gaap:AdditionalPaidInCapitalMember2023-12-310001600620us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001600620us-gaap:RetainedEarningsMember2023-12-310001600620us-gaap:CommonStockMember2024-01-012024-12-310001600620us-gaap:AdditionalPaidInCapitalMember2024-01-012024-12-310001600620us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-12-310001600620us-gaap:RetainedEarningsMember2024-01-012024-12-310001600620us-gaap:CommonStockMember2024-12-310001600620us-gaap:AdditionalPaidInCapitalMember2024-12-310001600620us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310001600620us-gaap:RetainedEarningsMember2024-12-310001600620auph:TwoSpecialtyPharmacyMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-01-012024-12-310001600620auph:TwoSpecialtyPharmacyMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-01-012023-12-310001600620srt:MinimumMemberus-gaap:IntellectualPropertyMember2024-01-012024-12-310001600620srt:MaximumMemberus-gaap:IntellectualPropertyMember2024-01-012024-12-310001600620us-gaap:EmployeeStockOptionMember2024-01-012024-12-310001600620us-gaap:PerformanceSharesMember2024-01-012024-12-310001600620us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-12-310001600620us-gaap:FairValueInputsLevel1Memberauph:CashCashEquivalentsAndRestrictedCashMember2024-12-310001600620us-gaap:FairValueInputsLevel2Memberauph:CashCashEquivalentsAndRestrictedCashMember2024-12-310001600620us-gaap:FairValueInputsLevel3Memberauph:CashCashEquivalentsAndRestrictedCashMember2024-12-310001600620auph:CashCashEquivalentsAndRestrictedCashMember2024-12-310001600620us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasuryBillSecuritiesMember2024-12-310001600620us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasuryBillSecuritiesMember2024-12-310001600620us-gaap:FairValueInputsLevel3Memberus-gaap:USTreasuryBillSecuritiesMember2024-12-310001600620us-gaap:USTreasuryBillSecuritiesMember2024-12-310001600620us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasuryBondSecuritiesMember2024-12-310001600620us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasuryBondSecuritiesMember2024-12-310001600620us-gaap:FairValueInputsLevel3Memberus-gaap:USTreasuryBondSecuritiesMember2024-12-310001600620us-gaap:USTreasuryBondSecuritiesMember2024-12-310001600620us-gaap:FairValueInputsLevel1Memberus-gaap:CommercialPaperMember2024-12-310001600620us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMember2024-12-310001600620us-gaap:FairValueInputsLevel3Memberus-gaap:CommercialPaperMember2024-12-310001600620us-gaap:CommercialPaperMember2024-12-310001600620us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateBondSecuritiesMember2024-12-310001600620us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateBondSecuritiesMember2024-12-31

SEC Form 10-K filed by Aurinia Pharmaceuticals Inc